OncoMatch/Lung Cancer — Small Cell (SCLC)/PD-L1 (CD274)
Lung Cancer — Small Cell (SCLC)PD-L1 (CD274) Clinical Trials
PD-L1 expression is assessed in SCLC primarily for atezolizumab eligibility; the IMpower133 regimen (atezolizumab + carboplatin/etoposide) is approved first-line for extensive-stage SCLC regardless of PD-L1 level, though high IC expression may enrich benefit. Durvalumab plus chemotherapy provides an alternative checkpoint-containing first-line option. Trials explore novel checkpoint combinations, anti-TIGIT agents, and ADC strategies in PD-L1-selected and unselected SCLC.
Top recruiting PD-L1 (CD274) Lung Cancer — Small Cell (SCLC) trials
Ranked by phase and US site count. See all 21 trials matched to your profile →
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Merck Sharp & Dohme LLC
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
ETOP IBCSG Partners Foundation
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Innate Pharma